What average weight loss percentage does semaglutide (Ozempic) actually produce?

The biggest myth: the Ozempic weight-loss percentage isn't really an Ozempic number

Spend ten minutes on social media and you'll see Ozempic credited with dramatic transformations. The weight-loss percentages circulating are real, but they belong to a different product. Ozempic contains semaglutide, and so does Wegovy. The molecule is the same. What differs is the licensed dose, the approved use, and the legal route to a prescription. Ozempic tops out at 2 mg weekly and is authorised by the MHRA for glycaemic control in type 2 diabetes. Wegovy starts lower, escalates to 2.4 mg weekly (and now 7.2 mg), and holds the UK weight-management licence.

This matters practically, not just technically. A GP who prescribes Ozempic to someone without diabetes would be prescribing off-label, outside the product's authorisation. The large clinical trials that produced the weight-loss percentages everyone quotes used the Wegovy formulation and dose schedule. Attributing those numbers to Ozempic as a weight-loss medicine is, at best, an oversimplification. At worst, it leads people to seek a medicine that is simply not the right legal or clinical fit for what they need.

The NHS semaglutide medicines page spells this out plainly: Ozempic is for diabetes, Wegovy is for weight management. Worth reading before drawing any conclusions from the figures below.

What semaglutide actually achieves for weight loss, the trial numbers

The STEP 1 trial is the study people are really referencing when they quote a semaglutide weight-loss percentage. Published in the New England Journal of Medicine (2021), it ran for 68 weeks, enrolled adults with obesity or overweight and at least one weight-related condition (no diabetes), and compared semaglutide 2.4 mg weekly against placebo alongside lifestyle support. If you want to understand what average weight loss on Wegovy looks like across the trial population, the figures break down more fully on that page, but in brief: the average reduction in body weight was around 15% on semaglutide, versus roughly 2.4% on placebo.

Fifteen percent is a clinically significant figure. For someone starting at 100 kg, that is approximately 15 kg. Across the trial population it reduced waist circumference, blood pressure and markers of metabolic risk alongside the scale number. However, a meaningful spread exists around that average: some participants lost considerably more, others less, and around 10% of people on semaglutide lost under 5% of their starting weight. Results depend on starting weight, adherence, the lifestyle changes running alongside treatment, and individual biology. No trial average is a personal forecast.

The MHRA approved a 7.2 mg single-dose pen in April 2026 following trial data showing around 20.7% average weight loss over 72 weeks, a result that sits closer to the tirzepatide 15 mg figures seen in SURMOUNT-5. If you want a fuller breakdown of how weekly numbers build over time, the detail is on our page covering average weight loss on Wegovy per week.

What is actually licensed for weight loss, and how to access it

In the UK, two injectable medicines hold weight-management licences: Wegovy (semaglutide) and Mounjaro (tirzepatide). Ozempic is not one of them. If a website is offering Ozempic prescriptions for weight loss, that is a red flag worth pausing on. Legitimate UK prescribers follow MHRA licensing; the GPhC register at pharmacyregulation.org lets you check any online pharmacy in under a minute.

Both licensed weight-loss medicines are Prescription-Only. That means a prescriber reviews your medical history, current BMI, and relevant conditions before any treatment is issued. Wegovy is recommended by NICE (TA875) for eligible adults; Mounjaro by NICE (TA1026, December 2024). Private treatment through a GPhC-registered pharmacy removes the NHS waiting list from the equation, provided you meet the clinical criteria.

If you are weighing up which medicine is more appropriate for your situation, the Wegovy overview covers the licensed dose schedule and eligibility in detail. For a broader look at what treatments are available through regulated private routes, the weight-loss treatment overview is a useful starting point. Questions about cost context sit on a separate page, and if you are wondering how long you are on Wegovy before results become apparent, that page also covers what ongoing treatment typically looks like. The Wegovy timeline page addresses how quickly results tend to emerge in the early weeks.

Semaglutide vs tirzepatide: does the percentage gap matter?

A fair question once the Ozempic confusion is cleared up: if Wegovy produces around 15% average loss at 2.4 mg, and Mounjaro around 20–21% at 15 mg, does the difference matter in practice? The SURMOUNT-5 trial (2025) ran the two head-to-head in adults with obesity and no diabetes and found tirzepatide produced meaningfully greater average weight reduction over 72 weeks. NICE's committee discussion noted indirect comparisons also favour tirzepatide. Wegovy at 7.2 mg narrows the gap substantially, though prescriber assessment determines which dose is right for any individual.

The honest answer is that percentages are one input, not the whole picture. Tolerability, your medical history, how long you plan to stay on treatment, and what your prescriber thinks is clinically appropriate all feed in. A decision best made in a consultation, not a comparison chart. If you are ready to have that conversation, speak to our prescribers through a free consultation, our clinical team, led by GPhC-registered Independent Prescribers, reviews every application personally the same day. That said, the semaglutide weight-loss percentage page covers the full evidence picture if you want to read further before booking.